02.17.15
AstraZeneca has adopted BioData’s Labguru platform, a web-based research and lab management system, for the global management of biological reagents used in preclinical research.
AstraZeneca will use the Labguru platform across multiple sites in North America and Europe, replacing and consolidating several legacy systems spanning several scientific disciplines. The system tracks projects, protocols, biological collections and materials, and is designed to streamline collaboration between members of the lab and institutions.
Lorenz Mayr, vice president of Reagents and Assay Development at AstraZeneca said, "We conducted a comprehensive evaluation and found Labguru to be the most suitable solution for the management of our global preclinical biological reagents. BioData's experience with supporting academic groups, together with the cloud-based Labguru installation, will allow AstraZeneca scientists greater opportunities to share our biological research reagents with future external partners, to support new drug discovery projects for which there is currently an unmet medical need."
AstraZeneca will use the Labguru platform across multiple sites in North America and Europe, replacing and consolidating several legacy systems spanning several scientific disciplines. The system tracks projects, protocols, biological collections and materials, and is designed to streamline collaboration between members of the lab and institutions.
Lorenz Mayr, vice president of Reagents and Assay Development at AstraZeneca said, "We conducted a comprehensive evaluation and found Labguru to be the most suitable solution for the management of our global preclinical biological reagents. BioData's experience with supporting academic groups, together with the cloud-based Labguru installation, will allow AstraZeneca scientists greater opportunities to share our biological research reagents with future external partners, to support new drug discovery projects for which there is currently an unmet medical need."